Ropinirole Hydrochloride transdermal (Hisamitsu Pharmaceutical)

盐酸罗匹尼罗透皮贴剂 (Hisamitsu Pharmaceutical)

Report date: 2025/05/15 16:39:22

Base Information

Drug NameRopinirole Hydrochloride transdermal (Hisamitsu Pharmaceutical)
Drug Alias NameHARUROPI TAPEHP 3000
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D2 receptor agonists
TargetsDopamine D2 receptor
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2019/09/20
Country/TerritoryJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHisamitsu Pharmaceutical Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesHisamitsu Pharmaceutical Co Inc
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A